Sponsor:
Cagent Vascular LLC
Code:
NCT05161039
Conditions
Peripheral Arterial Disease
Critical Limb Ischemia
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Serranator
POBA
Brief summary:
Conditions
Peripheral Arterial Disease
Critical Limb Ischemia
Study ID
NCT05161039
Start date
Nov 15, 2021
Status verified date
Jun, 2022
Completion date
Jul, 2022
Anticipated
Primary completion date
Jul, 2022
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
20 participants
Anticipated
Allocation
Non randomized
Intervention Model
Sequential
Primary purpose
Treatment
Arms
other: Serranator
other: POBA
Interventions
Serranator
POBA
Primary outcome measure
Central contacts
Locations
Stanford University
Recruiting
Palo Alto, California, United States, 94305
Sponsor
Cagent Vascular LLC
Last update posted
Jun 9, 2022
Last verified
Jun, 2022
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Cagent Vascular LLC on 2022-06-09.